Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Retinoblastoma Therapeutics market. The report identifies the key trends shaping and driving the global Retinoblastoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Retinoblastoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Retinoblastoma Therapeutics market. Its scope includes -
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
Summary
GlobalData, the industry analysis specialist, has released its new report, “Retinoblastoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Retinoblastoma Therapeutics market. The report identifies the key trends shaping and driving the global Retinoblastoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Retinoblastoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Retinoblastoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Retinoblastoma Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Retinoblastoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Retinoblastoma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Retinoblastoma Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Retinoblastoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Retinoblastoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Retinoblastoma Therapeutics market landscape? – Identify, understand and capitalize.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 RETINOBLASTOMA THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Most Common Pediatric Tumors
2.1.2 Congenital (Hereditary) and Non-Hereditary Retinoblastoma
2.1.3 Types of Retinoblastoma
2.2 Epidemiology
2.2.1 Incidence Rate
2.2.2 Survival Rate
2.2.3 Diagnosis Rate
2.2.4 Cure Rate
2.3 Etiology and Pathophysiology
2.3.1 Pathophysiology of Retinoblastoma
2.4 Sign and Symptoms
2.5 Prognosis
2.6 Diagnosis
2.6.1 Initial Diagnosis
2.6.2 Confirmatory Diagnosis
2.6.3 Grouping and Staging of Retinoblastoma
2.6.4 Histology
2.7 Treatment and Management Pattern
2.7.1 Management of Intraocular Retinoblastoma
2.7.2 Management of Extraocular Retinoblastoma
2.8 GlobalData Pipeline Report Guidance
3 RETINOBLASTOMA THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Global
3.2 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Global
3.3 Retinoblastoma Therapeutics Market Size (2006 - 2011) - The US
3.4 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - The US
3.5 Retinoblastoma Therapeutics Market Size (2006 - 2011) - The UK
3.6 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - The UK
3.7 Retinoblastoma Therapeutics Market Size (2006 - 2011) - France
3.8 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - France
3.9 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Germany
3.10 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Germany
3.11 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Italy
3.12 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Italy
3.13 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Spain
3.14 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Spain
3.15 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Japan
3.16 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Japan
3.17 Drivers and Barriers
3.17.1 Drivers for Retinoblastoma Therapeutics Market
3.17.2 Barriers for Retinoblastoma Therapeutics Market
3.18 Opportunity and Unmet Needs
3.19 Key Takeaway
4 RETINOBLASTOMA THERAPEUTICS MARKET - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Retinoblastoma Therapeutics Market
4.3.1 VEC Regimen (Vincristine + Carboplatin + Etoposide)
4.4 Key Takeaway
5 RETINOBLASTOMA THERAPEUTICS MARKET - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Retinoblastoma Pipeline Analysis - Pipeline by Clinical Phases of Development
5.3.1 Retinoblastoma Therapeutics-Phase II Pipeline
5.3.2 Retinoblastoma Therapeutics-Phase I Pipeline
5.4 Retinoblastoma Therapeutics Pipeline by Mechanism of Action
5.5 Retinoblastoma Therapeutics Technology Trends Analytic Framework
5.6 Promising Drugs under Clinical Development
5.7 Profile for Promising Drugs
6 RETINOBLASTOMA THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
7 RB THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 APPENDIX
8.1 Market Definitions
8.2 Abbreviations
8.3 Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Bibliography
LIST OF TABLES
Table 1: Hereditary and Non-Hereditary Retinoblastoma
Table 2: Annual Incidence of Retinoblastoma in EU 5 Countries
Table 3: Retinoblastoma Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Table 4: Retinoblastoma Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Table 5: Retinoblastoma Therapeutics Market, The US, Revenue ($), 2006 - 2011
Table 6: Retinoblastoma Therapeutics Market, The US, Forecast ($), 2011 - 2019
Table 7: Retinoblastoma Therapeutics Market, The UK, Revenue ($), 2006 - 2011
Table 8: Retinoblastoma Therapeutics Market, The UK, Forecast ($), 2011 - 2019
Table 9: Retinoblastoma Therapeutics Market, France, Revenue ($), 2006 - 2011
Table 10: Retinoblastoma Therapeutics Market, France, Forecast ($), 2011 - 2019
Table 11: Retinoblastoma Therapeutics Market, Germany, Revenue ($), 2006 - 2011
Table 12: Retinoblastoma Therapeutics Market, Germany, Forecast ($), 2011 - 2019
Table 13: Retinoblastoma Therapeutics Market, Italy, Revenue ($), 2006 - 2011
Table 14: Retinoblastoma Therapeutics Market, Italy, Forecast ($), 2011 - 2019
Table 15: Retinoblastoma Therapeutics Market, Spain, Revenue ($), 2006 - 2011
Table 16: Retinoblastoma Therapeutics Market, Spain, Forecast ($), 2011 - 2019
Table 17: Retinoblastoma Therapeutics Market, Japan, Revenue ($), 2006 - 2011
Table 18: Retinoblastoma Therapeutics Market, Japan, Forecast ($), 2011 - 2019
Table 19: Retinoblastoma Therapeutics- Phase II Pipeline, 2011
Table 20: Retinoblastoma Therapeutics - Phase I Pipeline, 2011
Table 21: Retinoblastoma Therapeutics - Promising Drug Under Clinical Development, 2011
Table 22: Retinoblastoma Therapeutics -Clinical Trials by Region, 2011
Table 23: Retinoblastoma Therapeutics, Global, Clinical Trials by Phase of Development, 2011
Table 24: Retinoblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2011
Table 25: Retinoblastoma Therapeutics, Overall Sponsors, 2011
Table 26: Retinoblastoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
LIST OF FIGURES
Figure 1: Most Common Pediatric Tumors
Figure 2: Solid Tumors in Pediatric Patients
Figure 3: Normal Retina and Retinoblastoma Tumor
Figure 4: Unilateral and Bilateral Retinoblastoma
Figure 5: The Gross Chalky White Appearance of Retinoblastoma
Figure 6: Molecular Genetic Mechanisms of Hereditary and Non-Hereditary Retinoblastoma
Figure 7: Percentage Breakdown of Common Symptoms of Retinoblastoma
Figure 8: Red Reflex Test to Detect Leukocoria
Figure 9: Major Diagnostic Tests for Retinoblastoma
Figure 10: CT Scan and Ultrasonography of Retinoblastoma
Figure 11: The Reese-Ellsworth Staging System
Figure 12: Histopathology Slide of Retinoblastoma
Figure 13: Multidisciplinary Approach in the Treatment of Retinoblastoma
Figure 14: Treatment Algorithm for the Management of Retinoblastoma, Unilateral
Figure 15: Treatment Algorithm for the Management of Retinoblastoma, Bilateral
Figure 16: Chemotherapy for Retinoblastoma
Figure 17: Orbital Implant During Enucleation
Figure 18: Retinoblastoma Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Figure 19: Retinoblastoma Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Figure 20: Retinoblastoma Therapeutics Market, The US, Revenue ($), 2006 - 2011
Figure 21: Retinoblastoma Therapeutics Market, The US, Forecast ($), 2011 - 2019
Figure 22: Retinoblastoma Therapeutics Market, The UK, Revenue ($), 2006 - 2011
Figure 23: Retinoblastoma Therapeutics Market, The UK, Forecast ($), 2011 - 2019
Figure 24: Retinoblastoma Therapeutics Market, France, Revenue ($), 2006 - 2011
Figure 25: Retinoblastoma Therapeutics Market, France, Forecast ($), 2011 - 2019
Figure 26: Retinoblastoma Therapeutics Market, Germany, Revenue ($), 2006 - 2011
Figure 27: Retinoblastoma Therapeutics Market, Germany, Forecast ($), 2011 - 2019
Figure 28: Retinoblastoma Therapeutics Market, Italy, Revenue ($), 2006 - 2011
Figure 29: Retinoblastoma Therapeutics Market, Italy, Forecast ($), 2011 - 2019
Figure 30: Retinoblastoma Therapeutics Market, Spain, Revenue ($), 2006 - 2011
Figure 31: Retinoblastoma Therapeutics Market, Spain, Forecast ($), 2011 - 2019
Figure 32: Retinoblastoma Therapeutics Market, Japan, Revenue ($), 2006 - 2011
Figure 33: Retinoblastoma Therapeutics Market, Japan, Forecast ($), 2011 - 2019
Figure 34: Opportunity and Unmet Need in the Retinoblastoma Therapeutics Market, 2011
Figure 35: Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma - CHP-582
Figure 36: Retinoblastoma Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 37: Technology Trends Analytic Framework of the Retinoblastoma Therapeutics Pipeline, 2011
Figure 38: Technology Trends Analytic Framework of the Retinoblastoma Therapeutics Pipeline- Description, 2011
Figure 39: Retinoblastoma Therapeutics -Clinical Trials by Region, 2011
Figure 40: Retinoblastoma Therapeutics, Global, Clinical Trials by Phase of Development, 2011
Figure 41: Retinoblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2011
Figure 42: Retinoblastoma Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011
Figure 43: Retinoblastoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
Figure 44: Retinoblastoma Therapeutics Market, Drivers and Restraints, 2011
Figure 45: Implications for Future Market Competition in the Retinoblastoma Therapeutics Market, 2011
Figure 46: GlobalData Market Forecasting Model
1.1 List of Tables
1.2 List of Figures
2 RETINOBLASTOMA THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Most Common Pediatric Tumors
2.1.2 Congenital (Hereditary) and Non-Hereditary Retinoblastoma
2.1.3 Types of Retinoblastoma
2.2 Epidemiology
2.2.1 Incidence Rate
2.2.2 Survival Rate
2.2.3 Diagnosis Rate
2.2.4 Cure Rate
2.3 Etiology and Pathophysiology
2.3.1 Pathophysiology of Retinoblastoma
2.4 Sign and Symptoms
2.5 Prognosis
2.6 Diagnosis
2.6.1 Initial Diagnosis
2.6.2 Confirmatory Diagnosis
2.6.3 Grouping and Staging of Retinoblastoma
2.6.4 Histology
2.7 Treatment and Management Pattern
2.7.1 Management of Intraocular Retinoblastoma
2.7.2 Management of Extraocular Retinoblastoma
2.8 GlobalData Pipeline Report Guidance
3 RETINOBLASTOMA THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Global
3.2 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Global
3.3 Retinoblastoma Therapeutics Market Size (2006 - 2011) - The US
3.4 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - The US
3.5 Retinoblastoma Therapeutics Market Size (2006 - 2011) - The UK
3.6 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - The UK
3.7 Retinoblastoma Therapeutics Market Size (2006 - 2011) - France
3.8 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - France
3.9 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Germany
3.10 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Germany
3.11 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Italy
3.12 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Italy
3.13 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Spain
3.14 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Spain
3.15 Retinoblastoma Therapeutics Market Size (2006 - 2011) - Japan
3.16 Retinoblastoma Therapeutics Market Forecast (2011 - 2019) - Japan
3.17 Drivers and Barriers
3.17.1 Drivers for Retinoblastoma Therapeutics Market
3.17.2 Barriers for Retinoblastoma Therapeutics Market
3.18 Opportunity and Unmet Needs
3.19 Key Takeaway
4 RETINOBLASTOMA THERAPEUTICS MARKET - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Retinoblastoma Therapeutics Market
4.3.1 VEC Regimen (Vincristine + Carboplatin + Etoposide)
4.4 Key Takeaway
5 RETINOBLASTOMA THERAPEUTICS MARKET - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Retinoblastoma Pipeline Analysis - Pipeline by Clinical Phases of Development
5.3.1 Retinoblastoma Therapeutics-Phase II Pipeline
5.3.2 Retinoblastoma Therapeutics-Phase I Pipeline
5.4 Retinoblastoma Therapeutics Pipeline by Mechanism of Action
5.5 Retinoblastoma Therapeutics Technology Trends Analytic Framework
5.6 Promising Drugs under Clinical Development
5.7 Profile for Promising Drugs
6 RETINOBLASTOMA THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
7 RB THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 APPENDIX
8.1 Market Definitions
8.2 Abbreviations
8.3 Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Bibliography
LIST OF TABLES
Table 1: Hereditary and Non-Hereditary Retinoblastoma
Table 2: Annual Incidence of Retinoblastoma in EU 5 Countries
Table 3: Retinoblastoma Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Table 4: Retinoblastoma Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Table 5: Retinoblastoma Therapeutics Market, The US, Revenue ($), 2006 - 2011
Table 6: Retinoblastoma Therapeutics Market, The US, Forecast ($), 2011 - 2019
Table 7: Retinoblastoma Therapeutics Market, The UK, Revenue ($), 2006 - 2011
Table 8: Retinoblastoma Therapeutics Market, The UK, Forecast ($), 2011 - 2019
Table 9: Retinoblastoma Therapeutics Market, France, Revenue ($), 2006 - 2011
Table 10: Retinoblastoma Therapeutics Market, France, Forecast ($), 2011 - 2019
Table 11: Retinoblastoma Therapeutics Market, Germany, Revenue ($), 2006 - 2011
Table 12: Retinoblastoma Therapeutics Market, Germany, Forecast ($), 2011 - 2019
Table 13: Retinoblastoma Therapeutics Market, Italy, Revenue ($), 2006 - 2011
Table 14: Retinoblastoma Therapeutics Market, Italy, Forecast ($), 2011 - 2019
Table 15: Retinoblastoma Therapeutics Market, Spain, Revenue ($), 2006 - 2011
Table 16: Retinoblastoma Therapeutics Market, Spain, Forecast ($), 2011 - 2019
Table 17: Retinoblastoma Therapeutics Market, Japan, Revenue ($), 2006 - 2011
Table 18: Retinoblastoma Therapeutics Market, Japan, Forecast ($), 2011 - 2019
Table 19: Retinoblastoma Therapeutics- Phase II Pipeline, 2011
Table 20: Retinoblastoma Therapeutics - Phase I Pipeline, 2011
Table 21: Retinoblastoma Therapeutics - Promising Drug Under Clinical Development, 2011
Table 22: Retinoblastoma Therapeutics -Clinical Trials by Region, 2011
Table 23: Retinoblastoma Therapeutics, Global, Clinical Trials by Phase of Development, 2011
Table 24: Retinoblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2011
Table 25: Retinoblastoma Therapeutics, Overall Sponsors, 2011
Table 26: Retinoblastoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
LIST OF FIGURES
Figure 1: Most Common Pediatric Tumors
Figure 2: Solid Tumors in Pediatric Patients
Figure 3: Normal Retina and Retinoblastoma Tumor
Figure 4: Unilateral and Bilateral Retinoblastoma
Figure 5: The Gross Chalky White Appearance of Retinoblastoma
Figure 6: Molecular Genetic Mechanisms of Hereditary and Non-Hereditary Retinoblastoma
Figure 7: Percentage Breakdown of Common Symptoms of Retinoblastoma
Figure 8: Red Reflex Test to Detect Leukocoria
Figure 9: Major Diagnostic Tests for Retinoblastoma
Figure 10: CT Scan and Ultrasonography of Retinoblastoma
Figure 11: The Reese-Ellsworth Staging System
Figure 12: Histopathology Slide of Retinoblastoma
Figure 13: Multidisciplinary Approach in the Treatment of Retinoblastoma
Figure 14: Treatment Algorithm for the Management of Retinoblastoma, Unilateral
Figure 15: Treatment Algorithm for the Management of Retinoblastoma, Bilateral
Figure 16: Chemotherapy for Retinoblastoma
Figure 17: Orbital Implant During Enucleation
Figure 18: Retinoblastoma Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Figure 19: Retinoblastoma Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Figure 20: Retinoblastoma Therapeutics Market, The US, Revenue ($), 2006 - 2011
Figure 21: Retinoblastoma Therapeutics Market, The US, Forecast ($), 2011 - 2019
Figure 22: Retinoblastoma Therapeutics Market, The UK, Revenue ($), 2006 - 2011
Figure 23: Retinoblastoma Therapeutics Market, The UK, Forecast ($), 2011 - 2019
Figure 24: Retinoblastoma Therapeutics Market, France, Revenue ($), 2006 - 2011
Figure 25: Retinoblastoma Therapeutics Market, France, Forecast ($), 2011 - 2019
Figure 26: Retinoblastoma Therapeutics Market, Germany, Revenue ($), 2006 - 2011
Figure 27: Retinoblastoma Therapeutics Market, Germany, Forecast ($), 2011 - 2019
Figure 28: Retinoblastoma Therapeutics Market, Italy, Revenue ($), 2006 - 2011
Figure 29: Retinoblastoma Therapeutics Market, Italy, Forecast ($), 2011 - 2019
Figure 30: Retinoblastoma Therapeutics Market, Spain, Revenue ($), 2006 - 2011
Figure 31: Retinoblastoma Therapeutics Market, Spain, Forecast ($), 2011 - 2019
Figure 32: Retinoblastoma Therapeutics Market, Japan, Revenue ($), 2006 - 2011
Figure 33: Retinoblastoma Therapeutics Market, Japan, Forecast ($), 2011 - 2019
Figure 34: Opportunity and Unmet Need in the Retinoblastoma Therapeutics Market, 2011
Figure 35: Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma - CHP-582
Figure 36: Retinoblastoma Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 37: Technology Trends Analytic Framework of the Retinoblastoma Therapeutics Pipeline, 2011
Figure 38: Technology Trends Analytic Framework of the Retinoblastoma Therapeutics Pipeline- Description, 2011
Figure 39: Retinoblastoma Therapeutics -Clinical Trials by Region, 2011
Figure 40: Retinoblastoma Therapeutics, Global, Clinical Trials by Phase of Development, 2011
Figure 41: Retinoblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2011
Figure 42: Retinoblastoma Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011
Figure 43: Retinoblastoma Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
Figure 44: Retinoblastoma Therapeutics Market, Drivers and Restraints, 2011
Figure 45: Implications for Future Market Competition in the Retinoblastoma Therapeutics Market, 2011
Figure 46: GlobalData Market Forecasting Model
